
Full text loading...
Poor drug solubility and permeability, particularly in BCS Class IV drugs, hamper their pharmacokinetics and targeted action. This study aims to address this by utilizing starch nanoparticles as a novel carrier for enhanced delivery and improved bioavailability. Formulation and evaluation of the QLSS nanoparticles as a drug delivery system.
Formulation of the QLSS nanoparticles and their % drug entrapment, drug loading, average particle size, surface morphological examination, in-vitro drug release study, and cytotoxicity activity using an MTT assay against the A549 cancer cell line.
QLSS nanoparticles were prepared by the nanoprecipitation technique with some modifications, &assessment, including surface morphological analysis, drug loading, drug entrapment percentage, average particle size, in-vitro drug release study, and cytotoxicity activity.
The average particle size and surface morphology of prepared optimized QLSS nanoparticles (QLSS 3) were found to be approximately 43.24-113.51 nm and spherical in shape with a 292.1nm Z-average size. The percentage yield was found to be 80 ± 2.0% of QLSS-3. Loading capacity and the percentages of drug encapsulation efficiency were found to be 42.5 ± 1.2% and 68 ± 2.2%, respectively. The results of the in-vitro drug's release were found to be 96.12 ± 1.8% within 12 hours. 10µg/ml of QLSS 3 inhibited 66.31 ± 1.4% of A549 cancer cells.
In this research study, sago starch was used for the first time as a drug carrier for quercetin. The results of the studies confirmed the improvement in pharmacokinetic parameters of the BCS-IV class drug.